Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · October 12, 2022

Outcomes of Low-Dose vs Very Low–Dose Bevacizumab Treatment in Infants With Retinopathy of Prematurity



Additional Info

Disclosure statements are available on the authors' profiles:

Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes
Ophthalmology 2022 Oct 01;129(10)1120-1128, SF Freedman, A Hercinovic, DK Wallace, RT Kraker, Z Li, AR Bhatt, CS Boente, ER Crouch, GB Hubbard, DL Rogers, D VanderVeen, MB Yang, NL Cheung, SA Cotter, JM Holmes,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading